Lyrica (Pregabalin) Is Not Indicated for Treating Involuntary Movements
Lyrica (pregabalin) is not an appropriate treatment for involuntary movements and may actually cause or worsen movement disorders. The FDA-approved indications for pregabalin are limited to neuropathic pain conditions (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, and adjunctive therapy for partial-onset seizures 1. Involuntary movements are not among these approved uses.
Critical Safety Concern: Pregabalin Can Cause Movement Disorders
The most concerning issue is that pregabalin itself is associated with causing involuntary movements as adverse effects, not treating them. According to FDA labeling, the most common neurological adverse effects include:
- Ataxia (incoordination and unsteady gait): 4-9% of patients 1
- Tremor: 1-2% of patients 1
- Abnormal gait: 1-4% of patients 1
- Incoordination: 2-3% of patients 1
A comprehensive literature review identified 305 cases of pregabalin-associated movement disorders, including 184 cases of ataxia, 61 with tremors, 39 with myoclonus, 8 with parkinsonism, and cases of dystonia, dyskinesia, and akathisia 2. These movement disorders typically occurred at a mean dose of 238 mg and developed within 1 month of starting pregabalin in 75% of cases 2.
When Involuntary Movements Occur: Established Treatments
The evidence-based approach to involuntary movements depends entirely on the underlying cause:
For Drug-Induced Extrapyramidal Symptoms (from antipsychotics):
Acute dystonia (sudden muscle spasms): Treat with anticholinergic agents (e.g., benztropine) or antihistamines, which provide rapid relief 3, 4, 3.
Akathisia (severe restlessness): First-line management includes lowering the antipsychotic dose if feasible, followed by β-blockers or benzodiazepines—not pregabalin 4.
Tardive dyskinesia (chronic involuntary facial/limb movements): The primary treatment is discontinuing or switching the offending antipsychotic, preferably to an atypical agent 4, 5.
For Sydenham Chorea:
The 2025 consensus guidelines recommend sodium valproate as the preferred symptomatic treatment for movement disorders in Sydenham chorea, with full consensus among experts 6. Dopamine antagonists (haloperidol, chlorpromazine) carry increased risk of side effects including dystonia and parkinsonism 6.
For Essential Tremor:
While small pilot studies suggested pregabalin might reduce tremor amplitude in essential tremor 7, 8, these were limited preliminary investigations. Pregabalin is not established or guideline-recommended for this indication.
For Restless Legs Syndrome:
The 2025 AASM guidelines provide a strong recommendation for pregabalin in restless legs syndrome (RLS), with moderate certainty of evidence 9. However, RLS is characterized by an urge to move the legs with uncomfortable sensations—not involuntary movements. This is a distinct condition from movement disorders like chorea, dystonia, or tremor.
Clinical Algorithm
If a patient presents with involuntary movements:
- Identify the type of movement disorder: dystonia, chorea, tremor, myoclonus, akathisia, parkinsonism, or tics
- Determine the underlying cause: medication-induced (especially antipsychotics), post-infectious (Sydenham chorea), neurodegenerative, metabolic, or idiopathic
- Do NOT prescribe pregabalin for involuntary movements
- If the patient is already on pregabalin and develops new involuntary movements: Strongly consider pregabalin as the cause and discontinue it. Recovery typically occurs within 1 week of withdrawal in 77% of cases 2
Key Pitfalls to Avoid
- Never use pregabalin to treat involuntary movements—it lacks efficacy for this indication and may worsen the condition
- Do not confuse restless legs syndrome with movement disorders—RLS involves sensory discomfort and voluntary movements to relieve it, not involuntary movements
- Recognize pregabalin-induced movement disorders early—they can occur at therapeutic doses and significantly impact quality of life
- Avoid combining pregabalin with other medications that cause ataxia or tremor without careful monitoring